Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls

Tuberculosis

Volumn 94, Issue 4, 2014, Pages 357-362

  Kakkar, Ashish Kumar ^a   Dahiya, Neha ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Bedaquiline; Diarylquinoline; MDR TB; Multidrug resistant tuberculosis

Indexed keywords

AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BEDAQUILINE; BILIRUBIN; MACROLIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFAMYCIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADVISORY COMMITTEE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERICIDAL ACTIVITY; BILATERAL HEARING LOSS; BILIRUBIN BLOOD LEVEL; CLINICAL PHARMACOLOGY; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; HYPERURICEMIA; LIMB PAIN; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; THORAX PAIN; TORSADE DES POINTES; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84902551306     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.04.001     Document Type: Review

References (30)

1. WHO Global tuberculosis report [Internet] 2013 WHO [cited 2013 Nov 6]. Available from: http://www.who.int/tb/publications/global-report/en/
2. WHO | Tuberculosis [Internet]. WHO. [cited 2013 Nov 6]. Available from:: http://www.who.int/mediacentre/factsheets/fs104/en/.
3. D. Falzon, E. Jaramillo, H.J. Schünemann, M. Arentz, M. Bauer, and J. Bayona et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Eur Respir J 38 3 2011 Sep 516 528
4. J.S. Mukherjee, M.L. Rich, A.R. Socci, J.K. Joseph, F.A. Virú, and S.S. Shin et al. Programmes and principles in treatment of multidrug-resistant tuberculosis Lancet 363 9407 2004 Feb 7 474 481
5. Stop TB Partnership, World Health Organization The global plan to stop TB 2011-2015 [Internet] 2010 Stop TB Partnership [cited 2013 Oct 25] Available from: http://www.stoptb.org/assets/documents/global/plan/TB- GlobalPlanToStopTB2011-2015.pdf
6. Z. Ma, C. Lienhardt, H. McIlleron, A.J. Nunn, and X. Wang Global tuberculosis drug development pipeline: the need and the reality Lancet 375 9731 2010 Jun 12 2100 2109
7. A. Koul, E. Arnoult, N. Lounis, J. Guillemont, and K. Andries The challenge of new drug discovery for tuberculosis Nature 469 7331 2011 Jan 27 483 490
8. B. Villemagne, C. Crauste, M. Flipo, A.R. Baulard, B. Déprez, and N. Willand Tuberculosis: the drug development pipeline at a glance Eur J Med Chem 51 2012 May 1 16
9. A. Matteelli, A.C. Carvalho, K.E. Dooley, and A. Kritski TMC207: the first compound of a new class of potent anti-tuberculosis drugs Future Microbiol 5 6 2010 Jun 849 858
10. [Internet] Food and Drug Administration (U.S.) FDA news release 31 December 2012 [cited 2013 Oct 25] Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm333695.htm
11. Food and Drug Administration (U.S.) [Internet]. Sirturo (bedaquiline): highlights of prescribing information [cited 2013 Oct 30] Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/204384s000lbl.pdf.
12. EC Grants Conditional Approval to Janssen TB Drug Drug discovery and development [Internet] 2014 Mar 6 [cited 2014 Mar 6]; Available from: http://www.dddmag.com/news/2014/03/ec-grants-conditional-approval-janssen-tb- drug
13. Food and Drug Administration Briefing package: sirturo 2012 Food and Drug Administration Washington, DC Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti- InfectiveDrugsAdvisoryCommittee/UCM329258.pdf
14. A.H. Diacon, P.R. Donald, A. Pym, M. Grobusch, R.F. Patientia, and R. Mahanyele et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrob Agents Chemother 56 6 2012 Jun 1 3271 3276
15. K. Andries, P. Verhasselt, J. Guillemont, H.W.H. Göhlmann, J.-M. Neefs, and H. Winkler et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 5707 2005 Jan 14 223 227
16. M. Ibrahim, K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, and V. Jarlier et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob Agents Chemother 51 3 2007 Mar 1011 1015
17. M. Ibrahim, C. Truffot-Pernot, K. Andries, V. Jarlier, and N. Veziris Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis Am J Respir Crit Care Med 180 6 2009 Sep 15 553 557
18. R. Tasneen, S.-Y. Li, C.A. Peloquin, D. Taylor, K.N. Williams, and K. Andries et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Antimicrob Agents Chemother 55 12 2011 Dec 5485 5492
19. R. Rustomjee, A.H. Diacon, J. Allen, A. Venter, C. Reddy, and R.F. Patientia et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis Antimicrob Agents Chemother 52 8 2008 Aug 2831 2835
20. A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, and L. Page-Shipp et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis N Engl J Med 360 23 2009 Jun 4 2397 2405
21. Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control 62 RR-09 2013 Oct 25 1 12
22. A. Diacon, A. Pym, M. Grobusch, J. De Los Rios, E. Gotuzzo, and I. Vasilyeva et al. Final 120-week results of a phase II randomised, double-blind, placebo-controlled study of 24-weeks bedaquiline treatment for MDR-TB (C208) [Internet]. Paris 2013 [cited 2014 Feb 28]. Available from: http://slideonline. eu/recordings/2013/union2013/
23. A. Pym, A. Diacon, F. Conradie, S. Tang, N. Bakare, and M. Haxaire-Theeuwes et al. Bedaquiline as part of a multidrug-resistant tuberculosis therapy regimen: interim and final results of a single-arm, phase II trial (C209) [Internet]. Paris 2013 [cited 2014 Feb 28]. Available from: http://slideonline.eu/recordings/2013/union2013/
24. A.H. Diacon, R. Dawson, F. von Groote-Bidlingmaier, G. Symons, A. Venter, and P.R. Donald et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380 9846 2012 Sep 15 986 993
25. [Internet] The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2013 World Health Organization Geneva [cited 2013 Nov 6]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK154134/
26. R.S. Wallis Surrogate markers to assess new therapies for drug-resistant tuberculosis Expert Rev Anti Infect Ther 5 2 2007 Apr 163 168
27. J. Avorn Approval of a tuberculosis drug based on a paradoxical surrogate measure J Am Med Assoc 309 13 2013 Apr 3 1349 1350
28. Hilary Marshall New drug approved for MDR tuberculosis, despite concerns [Internet] Lancet 2013 Jan Available from: http://download.thelancet.com/ flatcontentassets/lanres/edch/140113-2-1.pdf
29. W.R. Mac Kenzie, C.M. Heilig, L. Bozeman, J.L. Johnson, G. Muzanye, and D. Dunbar et al. Geographic differences in time to culture conversion in liquid media: tuberculosis trials consortium study 28. Culture conversion is delayed in africa PLoS One 6 4 2011 Apr 11 e18358
30. R. Prasad Is the new TB drug already being misused? [Internet] 2013 May 9 The Hindu [cited 2013 Nov 6]; Available from: http://www.thehindu.com/todays- paper/tp-business/is-the-new-tb-drug-already-being-misused/article4697678.ece